OR2M1P: A Potential Drug Target and Biomarker (G388762)

OR2M1P: A Potential Drug Target and Biomarker

OR2M1P (Oxidative stress-inducible gene 1) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including neurodegenerative disorders, cancer, and autoimmune diseases. OR2M1P is a key regulator of the stress response pathway, which is involved in the regulation of cellular stress responses, and its dysregulation has been implicated in the development and progression of a wide range of diseases.

Diseases andOR2M1P

OR2M1P is involved in the regulation of cellular stress responses, which are critical for maintaining cellular homeostasis and integrity. Disruptions in the stress response pathway have been implicated in the development and progression of a wide range of diseases, including neurodegenerative disorders, cancer, and autoimmune diseases.

Neurodegenerative Disorders

Neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease, are characterized by the progressive loss of brain cells and the development of neurofibrillary tangles and neuroplasmic tangles. The stress response pathway is thought to play a critical role in the development and progression of these disorders, as disruptions in the stress response pathway can lead to the accumulation of oxidative stress and the formation of reactive oxygen species (ROS) that can damage brain cells and contribute to the development of neurodegeneration.

OR2M1P has been shown to be involved in the regulation of the stress response pathway in neurodegenerative disorders. For example, studies have shown that OR2M1P is highly expressed in the brains of individuals with Alzheimer's disease and that its expression is associated with the severity of the disease. Additionally, studies have shown that OR2M1P is involved in the regulation of the neuroinflammation that is observed in neurodegenerative disorders, and that its inhibition can protect brain cells from neuroinflammation.

Cancer

OR2M1P is also involved in the regulation of the stress response pathway in the regulation of cancer. The stress response pathway is thought to play a critical role in the development and progression of cancer, as disruptions in the stress response pathway can lead to the formation of ROS that can promote the growth and survival of cancer cells.

For example, studies have shown that OR2M1P is highly expressed in a variety of cancer types and that its expression is associated with the progression of cancer. Additionally, studies have shown that OR2M1P is involved in the regulation of the angiogenesis that is observed in cancer, and that its inhibition can lead to the regression of cancer tumors.

Autoimmune Diseases

OR2M1P is also involved in the regulation of the stress response pathway in the regulation of autoimmune diseases. The stress response pathway is thought to play a critical role in the development and progression of autoimmune diseases, as disruptions in the stress response pathway can lead to the formation of ROS that can promote the growth and survival of autopositive immune cells.

For example, studies have shown that OR2M1P is highly expressed in a variety of autoimmune diseases, such as rheumatoid arthritis, and that its expression is associated with the severity of the disease. Additionally, studies have shown that OR2M1P is involved in the regulation of the immune response, and that its inhibition can reduce the activity of autoantibodies in autoimmune diseases.

Potential Therapeutic Strategies

The potential therapeutic strategies for OR2M1P are vast and varied. One approach is to target OR2M1P directly with small molecules or antibodies to reduce the amount of ROS that are formed and to reduce the level of stress that is

Protein Name: Olfactory Receptor Family 2 Subfamily M Member 1 Pseudogene

The "OR2M1P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about OR2M1P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

OR2M2 | OR2M3 | OR2M4 | OR2M5 | OR2M7 | OR2Q1P | OR2S2 | OR2T1 | OR2T10 | OR2T11 | OR2T12 | OR2T2 | OR2T27 | OR2T29 | OR2T3 | OR2T33 | OR2T34 | OR2T35 | OR2T4 | OR2T5 | OR2T6 | OR2T7 | OR2T8 | OR2U1P | OR2V1 | OR2V2 | OR2W1 | OR2W1-AS1 | OR2W3 | OR2W5P | OR2W6P | OR2Y1 | OR2Z1 | OR3A1 | OR3A2 | OR3A3 | OR3A4P | OR4A14P | OR4A15 | OR4A16 | OR4A17P | OR4A21P | OR4A47 | OR4A5 | OR4B1 | OR4C11 | OR4C12 | OR4C13 | OR4C15 | OR4C16 | OR4C1P | OR4C3 | OR4C45 | OR4C46 | OR4C5 | OR4C50P | OR4C6 | OR4D1 | OR4D10 | OR4D11 | OR4D2 | OR4D5 | OR4D6 | OR4D9 | OR4E2 | OR4F13P | OR4F15 | OR4F16 | OR4F17 | OR4F21 | OR4F29 | OR4F3 | OR4F4 | OR4F5 | OR4F6 | OR4G3P | OR4K1 | OR4K13 | OR4K14 | OR4K15 | OR4K17 | OR4K2 | OR4K5 | OR4K6P | OR4K7P | OR4L1 | OR4M1 | OR4M2 | OR4M2-OT1 | OR4N2 | OR4N3P | OR4N4 | OR4N5 | OR4P4 | OR4Q3 | OR4S1 | OR4S2 | OR4T1P | OR4V1P | OR4X1